Standing to Appeal in IPR Remains Even After Divesting Accused Products
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Written by: Jeremiah S. Helm, Ph.D. & Mark Kachner
GRIT ENERGY SOLUTIONS, LLC v. OREN TECHNOLOGIES, LLC
Before Prost, Newman, Wallach. On appeal from The Patent Trial and Appeal Board.
Summary: IPR petitioner has standing to appeal an adverse Board decision even after divesting the products previously accused of infringement.
Oren Technologies sued Grit Energy for patent infringement. During the pendency of the litigation, Grit transferred ownership of all accused products, and Oren and Grit stipulated to dismiss the infringement action without prejudice. Soon thereafter Grit petitioned for IPR. The Board ultimately found that Grit did not meet its burden to show the challenged claims were unpatentable. On appeal, Oren challenged Grit’s standing to appeal. The Federal Circuit held that Grit had standing. Because Oren previously sued Grit for patent infringement, and Oren is free to reassert those infringement claims (because dismissal was without prejudice), Grit faces a sufficient threat of litigation to maintain standing to appeal. Further, Grit’s divestment of the accused products did not absolve it of liability based on actions that occurred prior to the transfer.
Editor: Paul Stewart
More insights
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…
Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026)
CASE OF THE WEEK Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026) In our Case of the Week, the Federal Circuit affirmed summary judgment invalidating all claims of Enanta’s Patent No. 11,358,953 as…